NCT01373450View on ClinicalTrials.gov

Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Oxyntomodulin

3.0 pmol/kg/min as an intravenous (IV) infusion in the morning of the day of graded glucose infusion (GGI) (Day 1)

DRUG

Liraglutide 0.6 mg

Single subcutaneous dose in the evening of the day before the GGI (Day-1)

DRUG

Liraglutide 1.2 mg

Single subcutaneous dose in the evening of the day before the GGI (Day-1)

DRUG

Placebo for Oxyntomodulin

IV infusion in the morning of the day of GGI (Day 1)

DRUG

Placebo for Liraglutide

Single subcutaneous dose in the evening of the day before the GGI (Day-1)

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01373450 - Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222) | Biotech Hunter | Biotech Hunter